pCR的乳腺癌患者,还要不要进行辅助化疗?

2018-12-25 MedSci MedSci原创

一项综合性的、患者层面的荟萃分析显示,与治疗后残余疾病的患者相比,对新辅助治疗达到病理完全缓解(pCR)的乳腺癌患者,无事件生存率(EFS)和总生存率(OS)显著提高。 2018年圣安东尼奥乳腺癌研讨会(SABCS)上,哈佛医学院劳拉·斯普林(Laura Spring)博士介绍道:“我们研究的所有患者都接受了术前化疗,所以我们特别关注的是那些达到了pCR的患者”。 斯普林在一份声明中补充说

一项综合性的、患者层面的荟萃分析显示,与治疗后残余疾病的患者相比,对新辅助治疗达到病理完全缓解(pCR)的乳腺癌患者,无事件生存率(EFS)和总生存率(OS)显著提高。 2018年圣安东尼奥乳腺癌研讨会(SABCS)上,哈佛医学院劳拉·斯普林(Laura Spring)博士介绍道:“我们研究的所有患者都接受了术前化疗,所以我们特别关注的是那些达到了pCR的患者”。 斯普林在一份声明中补充说:“我们证明了pCR与较高的无事件生存率和总生存率密切相关,而且在手术后接受了额外的细胞毒性辅助化疗的患者与没有接受的患者之间,这种相关性是相似的。” 换句话说,在达到pCR的情况下,不需要额外的术后辅助化疗,因为额外的治疗并没有增加疗效。 斯普林及其同事进行了52项研究,涉及27895名患者。这些患者在接受三阴性乳腺癌(TNBC)、HER2+乳腺癌或激素受体阳性/HER2阴性(HR+/HER2-)乳腺癌的新辅助治疗后达到了pCR。此处pCR的定义为:在手术中切除的乳腺组织或淋巴结中,没有浸润性癌的迹象。 疾病复发的中位随访时间为48个月,而OS的中位随访时间为49.9个月。 在总体人群中,与接受新辅

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2144507, encodeId=cfd2214450e9e, content=<a href='/topic/show?id=76f41063549e' target=_blank style='color:#2F92EE;'>#pCR术后#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106354, encryptionId=76f41063549e, topicName=pCR术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4a16549775, createdName=bebe-, createdTime=Sat Jun 24 17:56:33 CST 2023, time=2023-06-24, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1419421, encodeId=8b991419421f5, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Thu Dec 27 05:36:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571148, encodeId=691915e1148da, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Thu Dec 27 05:36:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356426, encodeId=4d113564269b, content=思考很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 26 06:39:04 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2023-06-24 bebe- 来自辽宁省
  2. [GetPortalCommentsPageByObjectIdResponse(id=2144507, encodeId=cfd2214450e9e, content=<a href='/topic/show?id=76f41063549e' target=_blank style='color:#2F92EE;'>#pCR术后#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106354, encryptionId=76f41063549e, topicName=pCR术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4a16549775, createdName=bebe-, createdTime=Sat Jun 24 17:56:33 CST 2023, time=2023-06-24, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1419421, encodeId=8b991419421f5, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Thu Dec 27 05:36:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571148, encodeId=691915e1148da, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Thu Dec 27 05:36:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356426, encodeId=4d113564269b, content=思考很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 26 06:39:04 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2018-12-27 Tommy1950
  3. [GetPortalCommentsPageByObjectIdResponse(id=2144507, encodeId=cfd2214450e9e, content=<a href='/topic/show?id=76f41063549e' target=_blank style='color:#2F92EE;'>#pCR术后#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106354, encryptionId=76f41063549e, topicName=pCR术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4a16549775, createdName=bebe-, createdTime=Sat Jun 24 17:56:33 CST 2023, time=2023-06-24, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1419421, encodeId=8b991419421f5, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Thu Dec 27 05:36:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571148, encodeId=691915e1148da, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Thu Dec 27 05:36:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356426, encodeId=4d113564269b, content=思考很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 26 06:39:04 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2144507, encodeId=cfd2214450e9e, content=<a href='/topic/show?id=76f41063549e' target=_blank style='color:#2F92EE;'>#pCR术后#</a> , beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=106354, encryptionId=76f41063549e, topicName=pCR术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4a16549775, createdName=bebe-, createdTime=Sat Jun 24 17:56:33 CST 2023, time=2023-06-24, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1419421, encodeId=8b991419421f5, content=<a href='/topic/show?id=e290138682e' target=_blank style='color:#2F92EE;'>#PCR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13868, encryptionId=e290138682e, topicName=PCR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cc43496966, createdName=Tommy1950, createdTime=Thu Dec 27 05:36:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571148, encodeId=691915e1148da, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Thu Dec 27 05:36:00 CST 2018, time=2018-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=356426, encodeId=4d113564269b, content=思考很到位, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 26 06:39:04 CST 2018, time=2018-12-26, status=1, ipAttribution=)]
    2018-12-26 lovetcm

    思考很到位

    0

相关资讯

王永胜教授:乳腺癌腋窝淋巴结降级处理进展

在乳腺外科手术中,乳腺癌的腋窝降级处理以前哨淋巴结活检为基础,代表了乳腺外科学发展的最高地位。

王永胜教授:吡咯替尼在新辅助/辅助治疗中疗效出众,未来有望用于早期HER2+乳腺癌治疗

随着抗HER2药物的不断丰富,HER2+乳腺癌患者的预后得到极大的改善,生存得以不断延长。

重磅|落实健康扶贫工作共享乳腺癌规范诊疗

12月14日,由国家卫生健康委员会中国人口宣传教育中心和中国抗癌协会乳腺癌专业委员会(CBCS)首次共同主办,万宁市妇女联合会、万宁市卫生和计划生育委员会、万宁市人民医院承办,上海罗氏制药有限公司支持的“健康扶贫,关爱女性健康”—全国20城贫困地区及基层乳腺癌规范化诊疗培训及乳腺健康教育公益活动第五站在万宁市人民医院成功举办。

《中国临床肿瘤学会乳腺癌诊疗指南2018.V1》外科问题解读

新辅助化疗是局部晚期乳腺癌或炎性乳腺癌的规范疗法,可以使肿瘤降期以利于手术或将不可能手术转变为可以手术,一般应按照既定化疗方案周期数(6~8 个周期)内最大疗效的原则进行。新辅助化疗后的保乳与常规保乳术后局部复发率间差异无统计学意义,新辅助化疗后保乳切除范围应根据肿瘤初始状况、分子亚型、肿瘤化疗后退缩模式等综合考虑,切缘阴性是基本原则。新辅助化疗后的前哨淋巴结活检(SLNB)争议较多,对cN0 病

CLIN CANCER RES:PTHrP预测乳腺癌患者不良预后

甲状旁腺激素相关蛋白(PTHrP)是正常乳腺发育所必需的。PTHLH基因多态性与乳腺癌风险有关,并且PTHrP促进溶骨性乳腺癌的骨转移生长。因此,目前认为PTHrP在恶性原发性乳腺肿瘤中上调,但缺少这种假设的确凿证据。CLIN CANCER RES近期发表了一篇文章研究这一问题。

2018 SABCS 十大受关注的乳腺癌研究

2018年圣安东尼奥乳腺癌研讨会(SABCS)于12月4-8日在美国圣安东尼奥盛大召开,自1978年成立以来,SABCS已从默默无名的一个地区性会议成长为吸引来自90多个国家的乳腺癌临床医生和研究人员参与的盛会。本次会议上公布了一系列可能改变乳腺癌临床实践的研究,对此我们进行了梳理。01.低剂量他莫昔芬治疗DCIS有效III期TAM-01研究显示,对于乳腺导管原位癌(DCIS)、小叶原位癌(L